Ptc Therapeutics (PTCT) Operating Leases (2019 - 2026)

Ptc Therapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $90.1 million for Q1 2026.

• In Q1 2026, Operating Leases rose 5.94% year-over-year to $90.1 million; the TTM figure through Mar 2026 stood at $90.1 million (up 5.94% YoY), while the FY2025 annual figure was $93.6 million, up 24.87% from the prior year.
• Operating Leases was $90.1 million for Q1 2026 at Ptc Therapeutics, down from $93.6 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $137.4 million in Q2 2022 to a low of $72.4 million in Q1 2022.
• Historically, Operating Leases has averaged $98.3 million across 5 years, with a median of $97.6 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Operating Leases soared 79.72% in 2022, then declined 23.23% in 2024.
• A 5-year view of Operating Leases shows it stood at $100.9 million in 2022, then slipped by 3.21% to $97.6 million in 2023, then fell by 23.23% to $74.9 million in 2024, then advanced by 24.87% to $93.6 million in 2025, then fell by 3.75% to $90.1 million in 2026.
• The last three Operating Leases figures came in at $90.1 million (Q1 2026), $93.6 million (Q4 2025), and $107.3 million (Q3 2025), per Business Quant data.